{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper defines Parkinson disease (PD) as a neurodegenerative disorder characterized by loss of dopaminergic neurons in the pars compacta of the substantia nigra, with LRRK2 mutations explaining between 5 and 13% of the familial and 1 and 5% of sporadic PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used in vitro kinase assays to measure the kinase activity of LRRK2 variants, which is relevant to the disease mechanism as LRRK2 kinase domain mutations are known to increase kinase activity, associated with higher apoptotic cell death in dopaminergic cell lines.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used effectively models the disease pathogenesis/mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of wild-type (WT), p.R1628P, and p.G2385R in kinase assays, with controls including vector control and specific phosphorylation substrates. The assays were performed with multiple replicates (n=4).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were used, meeting the criteria for proceeding to Sub-step 3c.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study used known pathogenic variants (e.g., p.G2019S) as controls and compared the kinase activity of p.G2385R to WT and other variants.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used, including known pathogenic variants, meeting the criteria for proceeding to Step 4.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper provides statistical analyses showing p.G2385R has significantly higher kinase activity compared to WT (p<0.05), with fold increase in MPU±SD (n=4).",
          "judgment": "Yes",
          "reasoning": "Statistical analyses are sufficient to estimate the effect size, indicating increased kinase activity for p.G2385R.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The relative risk of p.G2385R was calculated as 1.51 (95% CI: 1.35-1.65), indicating a moderate increase in risk.",
          "judgment": "Yes",
          "reasoning": "The OddsPath value indicates a moderate increase in risk, corresponding to PS3_moderate strength.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The p.G2385R variant in LRRK2 shows increased kinase activity, consistent with a pathogenic mechanism in PD, supported by statistical analyses and variant controls, warranting a PS3_moderate strength rating."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1398"
        },
        "variant_string_id": "LRRK2 R1398H"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper defines Parkinson disease (PD) as a neurodegenerative disorder characterized by loss of dopaminergic neurons in the pars compacta of the substantia nigra, with LRRK2 mutations explaining between 5 and 13% of the familial and 1 and 5% of sporadic PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used in vitro kinase assays to measure the kinase activity of LRRK2 variants, which is relevant to the disease mechanism as LRRK2 kinase domain mutations are known to increase kinase activity, associated with higher apoptotic cell death in dopaminergic cell lines.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used effectively models the disease pathogenesis/mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of wild-type (WT), p.R1398H, and other variants in kinase assays, with controls including vector control and specific phosphorylation substrates. The assays were performed with multiple replicates (n=4).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were used, meeting the criteria for proceeding to Sub-step 3c.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study used known pathogenic variants (e.g., p.G2019S) as controls and compared the kinase activity of p.R1398H to WT and other variants.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used, including known pathogenic variants, meeting the criteria for proceeding to Step 4.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper provides statistical analyses showing p.R1398H has significantly lower kinase activity compared to WT (p<0.001), with fold increase in MPU±SD (n=4).",
          "judgment": "Yes",
          "reasoning": "Statistical analyses are sufficient to estimate the effect size, indicating decreased kinase activity for p.R1398H.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The relative risk of p.R1398H was calculated as 0.86 (95% CI: 0.77-0.97), indicating a protective effect.",
          "judgment": "Yes",
          "reasoning": "The OddsPath value indicates a protective effect, corresponding to BS3_moderate strength.",
          "next_step_or_outcome": "Assign BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "The p.R1398H variant in LRRK2 shows decreased kinase activity, consistent with a protective effect in PD, supported by statistical analyses and variant controls, warranting a BS3_moderate strength rating."
    }
  ]
}